One-stage Assay for Hageman Factor (Factor XII). Further Studies on the Role of Hageman Factor in Blood Coagulation

Summary

A one stage assay for Hageman Factor (HF) activity is described. Maximal standardization was achieved by lyophilizing substrate plasma, cephalin suspension and standard reference plasma in small aliquots. A dilution curve was constructed, using a highly purified HF preparation. The assay is not completely specific and is invalidated by the presence of activated Factor IX and XI. So all materials to be tested were first adsorbed on Al(OH)₃-gel to exclude Factor IX and possibly most of Factor XI.

Purified activated HF still possesses a high affinity for glass surfaces, thus activation may not alter the molecule at the side of affinity for the glass surface. Moreover purified activated HF is still more active in the presence of glass thus in the adsorbed state. These observations support the idea that the so called activation of Hageman Factor is a reversible phenomenon, whereby the molecule unfolds and uncovers active groups as soon as it is adsorbed on a negatively charged surface.

^* This study was supported in part by the Organisation for Health Research, T N O, the Netherlands.

• References

• 1 Bergsagel D. E. The role of calcium in the activation of the Christmas factor. Brit. J. Haemat. l: 199 1955;
• 2 Haanen C, Hommes F, Benraad H, Morselt G. A case of Hageman Factor deficiency and a method to purify the factor. Thrombos. Diathes haemorrh. (Stuttg) 05: 201 1961;
• 3 Haanen C, Hommes F, Morselt G. Some observations on the role of Hageman Factor in blood coagulation. Thrombos. Diathes. haemorrh. (Stuttg) 06: 261 1961;
• 4 Hardisty R. M, Margolis J. The role of Hageman Factor in the initiation of blood coagulation. Brit. J. Haemat. 05: 203 1959;
• 5 Koller F, Loeliger A, Duckert F. Experiments on a new clotting factor (factor VII). Acta haemat. (Basel) 06: 1 1951;
• 6 Langdell R. D, Wagner R. H, Brinkhous K. M. Effect of anti- haemophilic factor on one-stage clotting tests. J. Lab. clin. Med. 41: 637 1953;
• 7 Margolis J. The kaolin clotting time. J. Clin. Path. 11: 406 1958;
• 8 Owren P. A. The coagulation of blood. Investigations on a new clotting factor. Thesis. Acta med. Scand. 128 suppl. 194 1947;
• 9 Owren P. A, Aas K. The control of dicumarol therapy and the quantitative determination of prothrombin and proconvertin. Scand. J. clin. Lab. Invest. 03: 201 1951;
• 10 Rapaport S. I, Schiffman S, Patch M. J, Ware A. G. A simple, specific one-stage assay for Plasma Thromboplastin Antecedent activity. J. Lab. clin. Med. 57: 771 1961;
• 11 Ratnoff O. D. A familial trait characterized by deficiency of a clotpromoting fraction of plasma. J. Lab. clin. Med. 44: 915 1954;
• 12 Ratnoff O. D, Rosenblum J. M. Role of Hageman Factor in the initiation of clotting by glass. Amer. J. Med. 25: 160 1958;
• 13 Ratnoff O. D. Hageman Trait. Thrombos. Diathes. haemorrh. (Stuttg) 04 suppl. 116 1960;
• 14 Ratnoff O. D, Davie E. W. The purification of activated Hageman Factor (Activated Factor XII). Biochem. 01: 967 1962;
• 15 Schoenmakers J. G, Kurstjens R. M, Haanen C. A, Zilliken F. Purification of activated bovine Hageman Factor. Fed. Proc. April 16-20 1963
• 16 Soulier J. P, Wartelle O, Ménaché D. Hageman trait and P. T. A. deficiency. Brit. J. Haemat. 05: 121 1959;